Entacapone

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 685 publications

Tailoring lipid-polymer hybrid nanoparticles as smart nanocarriers for entacapone delivery for managing Parkinson's disease.

Tailoring lipid-polymer hybrid nanoparticles as smart nanocarriers for entacapone delivery for managing Parkinson's disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 26, 2026

Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Four-Period Crossover Study Under Fasting and Fed Conditions.

Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Four-Period Crossover Study Under Fasting and Fed Conditions.

Journal: Clinical pharmacology in drug development

Published: March 22, 2026

Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease.

Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: March 11, 2026

Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database.

Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database.

Journal: Arquivos de neuro-psiquiatria

Published: January 25, 2026

Recent Developments in the Drug Treatment of Parkinson's Disease.

Recent Developments in the Drug Treatment of Parkinson's Disease.

Journal: Drugs

Published: January 15, 2026

CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease.

CauReL: Dynamic Counterfactual Learning for Precision Drug Repurposing in Alzheimer's Disease.

Journal: Research square

Published: January 09, 2026

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment

Pharmacokinetics and pharmacodynamics of anti-Parkinson drugs in geriatric patients : Key for optimization of treatment

Journal: Zeitschrift fur Gerontologie und Geriatrie

Published: December 19, 2025

Resolving spectral overlaps in Anti-Parkinson drug combinations: a green spectrophotometric approach for entacapone determination.

Resolving spectral overlaps in Anti-Parkinson drug combinations: a green spectrophotometric approach for entacapone determination.

Journal: BMC chemistry

Published: December 18, 2025

Case Report: A possible novel adult-onset, progressive MAO-A hypofunction.

Case Report: A possible novel adult-onset, progressive MAO-A hypofunction.

Journal: Frontiers in neuroscience

Published: December 01, 2025

Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.

Efficacy of MAO-B and COMT inhibitors on quality of life in patients with Parkinson's disease: a Bayesian network meta-analysis.

Journal: Frontiers in neurology

Published: November 24, 2025

Patient-reported outcomes and experiences with COMT inhibitors in the management of motor fluctuations in Parkinson's disease: a UK-based nested cross-sectional study.

Patient-reported outcomes and experiences with COMT inhibitors in the management of motor fluctuations in Parkinson's disease: a UK-based nested cross-sectional study.

Journal: Journal of neurology

Published: November 24, 2025

Consensus Molecules Associated with Parkinson's Disease.

Consensus Molecules Associated with Parkinson's Disease.

Journal: Neurology international

Published: November 20, 2025

Showing 1-12 of 685

Last Updated: 06/30/2026